Cyclosporine Soft Capsules

The main drug of cyclosporine capsules, cyclosporine (also known as cyclosporine A), is a cyclic polypeptide composed of 11 amino acids. This product is a powerful immunosuppressant that acts reversibly and specifically on lymphocytes. Animal experiments have shown that cyclosporine can prolong the survival time of allogeneic organ (skin, heart, kidney, pancreas, bone marrow, small intestine and lung) transplants and inhibit cell-mediated immune responses (including allogeneic immune responses, delayed cutaneous hypersensitivity reactions, experimental allergic encephalomyelitis, Freund's adjuvant arthritis, graft-versus-host reactions and T-cell-dependent antibody production). This product can also inhibit the synthesis and release of lymphokines (including IL-2) and block the G0 phase and early G1 phase of the lymphocyte growth cycle. This product does not inhibit erythropoiesis and does not affect the function of phagocytes. Usage

The main ingredient of this product is ciclosporin, and its chemical name is: cyclo(E)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino-6-octenyl-L-α-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-valyl. Molecular formula C62H111N11O12 molecular weight 1202.625

1. Prevent and treat rejection or graft-versus-host reaction of allogeneic organ transplantation or bone marrow transplantation. 2. Autoimmune diseases such as lupus nephritis and refractory nephrotic syndrome that are ineffective after other immunosuppressive agents.

1 Organ transplantation: When using a triple immunosuppressive regimen, the starting dose is 6-11 mg/kg/day, and the dose is adjusted according to the blood drug concentration. The dose is reduced by 0.5-1 mg/kg/day every 2 weeks according to the blood drug concentration. The maintenance dose is 2-6 mg/kg/day, taken orally in 2 divided doses. The entire treatment process must be carried out under the guidance of a physician with experience in immunosuppressive treatment. 2 Bone marrow transplantation: Prevention of GVHD: Starting from the day before transplantation, cyclosporine injection, 2.5 mg/kg/day, is administered intravenously in 2 doses. After the gastrointestinal reaction disappears (about 0.5 to 1 month), switch to this product, with an initial dose of 6 mg/kg/day, taken orally in 2 divided doses. After one month, the dose is slowly reduced, and the total course of treatment is about half a year. Treatment of GVHD: Use alone or in addition to the original use of adrenocortical hormones.

1. The more common gastrointestinal reactions include anorexia, nausea, vomiting, etc., gingival hyperplasia with bleeding and pain, and about 1/3 of the users experience nephrotoxicity. Renal function damage, hypertension, etc. may occur, such as increased serum creatinine and urea nitrogen, decreased glomerular filtration rate, etc. Gingival hyperplasia generally disappears 6 months after stopping the drug. Chronic, progressive nephrotoxicity usually occurs about 12 months after treatment. 2. Uncommon symptoms include convulsions, which may be caused by the nephrotoxicity and hypomagnesemia of this product. In addition, this product can also cause increased aminotransferase, cholestasis, hyperbilirubinemia, hyperglycemia, hirsutism, hand tremor, hyperuricemia with thrombocytopenia, microangiopathic hemolytic anemia, paresthesia of the limbs, painful cramps of the lower limbs, etc. In addition, there are reports that this product can promote ADP-induced platelet aggregation and increase thromboxane A

1. Patients who are allergic to cyclosporine. 2. Patients with severe liver or kidney damage, uncontrolled hypertension, infection or malignant tumors should not use or use with caution.

There have been reports of many drug interactions with this product. The following interactions are summarized based on a large amount of data and are considered to be clinically significant. A review entitled Interactions between Santobuc and Drugs, which lists all known interactions, including those with only a single dose or controversial reports, is available upon request. Drugs that can increase nephrotoxicity Acyclovir, aminoglycoside antibiotics (including gentamicin and tobramycin), amphotericin B, ciprofloxacin, furosemide, mannitol, melphalan, methoxazole (sulfamethoxazole), vancomycin, nonsteroidal anti-inflammatory drugs (including diclofenac, indomethacin, naproxen, and sulindac) Drugs that can reduce cyclosporine blood levels Barbiturates, imipenem, phenytoin, neopentyl penicillin III, sulfamethoxazole intravenous

Store tightly closed in a cool, dry place away from light. Remove from foil packaging only before consumption.

25 mg